

IVIG Comparison Chart
Our Lady of the Lake Regional Medical Center
Department of Pharmacy

Carimune NF, our formulary IVIG product, is on national backorder. Privigen will be the IVIG product of choice until the shortage resolves. Listed below is a comparison of Privigen and Carimune. Gammunex (non-formulary) is also listed for reference purposes.

Product	Privigen (latex-free)	Carimune NF	Gammunex (latex-free)
Indications	PI, Chronic ITP	PI, Acute & Chronic ITP	PI, ITP, CIDP
Contraindications	Patients with IgA deficiencies, antibodies to IgA, and previous severe systemic reactions to IVIG. Privigen® is contraindicated in patients with hyperprolinemia.		
IgG Content	98%	≥ 96%	≥98%
IgA Content	≤ 25 mcg/mL	Trace	46mcg/mL
Osmolality	240-440mOsm/kg	In sterile water: 192-768mOsm/kg In 0.9% NaCl: 498-1074mOsm/kg In 5% Dextrose: 444-1020mOsm/kg	258 mOsm/kg
Sugar Content	None (L-proline stabilized)	5% Sucrose	None (glycine stabilized)
Sodium Content	Trace	<20mg/g of protein	Trace
pH of Liquid Product	4.6 - 5.0	6.4 - 6.8 (after reconstitution)	4.0-4.5
Product Half Life	36.6 days	21 days	35 days
Formulation	Ready-to-use liquid	Lyophilized powder for reconstitution	Ready-to-use liquid
Concentrations	10% liquid: 5 g, 10 g, 20 g	3 – 12% powder: 3 g, 6 g, and 12 g vials	10% Liquid: 1g, 2.5g, 5g, 10g, 20g
Dose	Chronic ITP: 1g/kg load, 2g/kg maintenance PI: 200-800mg/kg	Acute & Chronic ITP: 0.4-0.8g/kg PI: 0.2-0.3g/kg	ITP: 2g/kg PI: 300-600mg/kg CIDP: 2g/kg load, 1g/kg maintenance
Initial Infusion rate	0.5mg/kg/min	0.5mg/kg/min	ITP, PI: 1mg/kg/min CIDP: 2mg/kg/min
Max Infusion Rate	Chronic ITP: 4mg/kg/min PI: 8mg/kg/min >65, renal disease: <2mg/kg/min	<2mg/kg/min Renal disease: <0.02ml/kg/min	8mg/kg/min
Compatible Diluents	D5W (may flush line with D5W or NS)	Reconstituted: sterile water, D5W, and NS	D5W
Reconstitution Time	Ready to use liquid	Up to 1 hour	Ready to use liquid
Adverse events	Rates are variable and patient-specific. Volume load, sugar content, sodium content, osmolality, pH, and development of anti-IgA antibodies all impact a patient's risk of having an adverse event. For that reason, IVIG should be used with caution in the following patient populations: cardiac impairment, renal dysfunction, anti-IgA antibody presence, thromboembolic risk, diabetes, elderly patients, and neonate/pediatric patients.		

References

1. Gammunex product insert. Talecris Biotherapeutics, Inc. October 2010 Research Triangle Park, NC
2. Privigen product insert. CSL Behring, LLC. July 2007 Kankakee, IL
3. Carimune product insert. ZLB Behring, LLC. October 2008 Kankakee, IL